Literature DB >> 27325104

Pediatric-type nodal follicular lymphoma: a biologically distinct lymphoma with frequent MAPK pathway mutations.

Abner Louissaint1, Kristian T Schafernak2, Julia T Geyer3, Alexandra E Kovach4, Mahmoud Ghandi5, Dita Gratzinger6, Christine G Roth7, Christian N Paxton8, Sunhee Kim9, Chungdak Namgyal10, Ryan Morin11, Elizabeth A Morgan10, Donna S Neuberg12, Sarah T South13, Marian H Harris4, Robert P Hasserjian14, Ephraim P Hochberg15, Levi A Garraway16, Nancy Lee Harris14, David M Weinstock16.   

Abstract

Pediatric-type nodal follicular lymphoma (PTNFL) is a variant of follicular lymphoma (FL) characterized by limited-stage presentation and invariably benign behavior despite often high-grade histological appearance. It is important to distinguish PTNFL from typical FL in order to avoid unnecessary treatment; however, this distinction relies solely on clinical and pathological criteria, which may be variably applied. To define the genetic landscape of PTNFL, we performed copy number analysis and exome and/or targeted sequencing of 26 PTNFLs (16 pediatric and 10 adult). The most commonly mutated gene in PTNFL was MAP2K1, encoding MEK1, with a mutation frequency of 43%. All MAP2K1 mutations were activating missense mutations localized to exons 2 and 3, which encode negative regulatory and catalytic domains, respectively. Missense mutations in MAPK1 (2/22) and RRAS (1/22) were identified in cases that lacked MAP2K1 mutations. The second most commonly mutated gene in PTNFL was TNFRSF14, with a mutation frequency of 29%, similar to that seen in limited-stage typical FL (P = .35). PTNFL was otherwise genomically bland and specifically lacked recurrent mutations in epigenetic modifiers (eg, CREBBP, KMT2D). Copy number aberrations affected a mean of only 0.5% of PTNFL genomes, compared with 10% of limited-stage typical FL genomes (P < .02). Importantly, the mutational profiles of PTNFLs in children and adults were highly similar. Together, these findings define PTNFL as a biologically and clinically distinct indolent lymphoma of children and adults characterized by a high prevalence of MAPK pathway mutations and a near absence of mutations in epigenetic modifiers.
© 2016 by The American Society of Hematology.

Entities:  

Mesh:

Year:  2016        PMID: 27325104      PMCID: PMC5000844          DOI: 10.1182/blood-2015-12-682591

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  30 in total

Review 1.  Non-Hodgkin's lymphomas involving the uterus: a clinicopathologic analysis of 26 cases.

Authors:  R Vang; L J Medeiros; C S Ha; M Deavers
Journal:  Mod Pathol       Date:  2000-01       Impact factor: 7.842

Review 2.  A case of primary MALT lymphoma of the endometrium presenting as an asymptomatic polyp.

Authors:  O Annibali; A A Romeo; C Agostinelli; F Marchesi; A Natale; M De Muro; M C Tirindelli; S A Pileri; G Avvisati
Journal:  Ann Hematol       Date:  2008-10-11       Impact factor: 3.673

3.  Primary lymphomas of the cervix and uterus: the University of Pennsylvania's experience and a review of the literature.

Authors:  Noelle V Frey; Jakub Svoboda; Charalambos Andreadis; Donald E Tsai; Stephen J Schuster; Rebecca Elstrom; Stephen C Rubin; Sunita D Nasta
Journal:  Leuk Lymphoma       Date:  2006-09

4.  BRAF and MAP2K1 mutations in Langerhans cell histiocytosis: a study of 50 cases.

Authors:  Khaled Alayed; L Jeffrey Medeiros; Keyur P Patel; Zhuang Zuo; Shaoying Li; Shalini Verma; John Galbincea; R Craig Cason; Rajyalakshmi Luthra; C Cameron Yin
Journal:  Hum Pathol       Date:  2016-02-01       Impact factor: 3.466

Review 5.  Marginal zone B-cell lymphoma of the uterus: a case report and review of the literature.

Authors:  Mehdi Hamadani; M Kharfan-Dabaja; Rammurti Kamble; William Kern; Howard Ozer
Journal:  J Okla State Med Assoc       Date:  2006-04

6.  Low frequency clonal mutations recoverable by deep sequencing in patients with aplastic anemia.

Authors:  A A Lane; O Odejide; N Kopp; S Kim; A Yoda; R Erlich; N Wagle; G A Abel; S J Rodig; J H Antin; D M Weinstock
Journal:  Leukemia       Date:  2013-02-01       Impact factor: 11.528

7.  Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis.

Authors:  Rikhia Chakraborty; Oliver A Hampton; Xiaoyun Shen; Stephen J Simko; Albert Shih; Harshal Abhyankar; Karen Phaik Har Lim; Kyle R Covington; Lisa Trevino; Ninad Dewal; Donna M Muzny; Harshavardhan Doddapaneni; Jianhong Hu; Linghua Wang; Philip J Lupo; M John Hicks; Diana L Bonilla; Karen C Dwyer; Marie-Luise Berres; Poulikos I Poulikakos; Miriam Merad; Kenneth L McClain; David A Wheeler; Carl E Allen; D Williams Parsons
Journal:  Blood       Date:  2014-09-08       Impact factor: 22.113

8.  Children and adolescents with follicular lymphoma have an excellent prognosis with either limited chemotherapy or with a "Watch and wait" strategy after complete resection.

Authors:  Andishe Attarbaschi; Auke Beishuizen; Georg Mann; Angelo Rosolen; Tetsuya Mori; Anne Uyttebroeck; Felix Niggli; Monika Csoka; Zdenka Krenova; Karin Mellgren; Edita Kabickova; Alan Ks Chiang; Alfred Reiter; Denise Williams; Birgit Burkhardt
Journal:  Ann Hematol       Date:  2013-05-12       Impact factor: 3.673

9.  Pediatric-type nodal follicular lymphoma: an indolent clonal proliferation in children and adults with high proliferation index and no BCL2 rearrangement.

Authors:  Abner Louissaint; Adam M Ackerman; Dora Dias-Santagata; Judith A Ferry; Ephraim P Hochberg; Mary S Huang; A John Iafrate; Daniel O Lara; Geraldine S Pinkus; Itziar Salaverria; Zakir Siddiquee; Reiner Siebert; Howard J Weinstein; Lawrence R Zukerberg; Nancy Lee Harris; Robert P Hasserjian
Journal:  Blood       Date:  2012-07-31       Impact factor: 22.113

10.  Solution hybrid selection with ultra-long oligonucleotides for massively parallel targeted sequencing.

Authors:  Andreas Gnirke; Alexandre Melnikov; Jared Maguire; Peter Rogov; Emily M LeProust; William Brockman; Timothy Fennell; Georgia Giannoukos; Sheila Fisher; Carsten Russ; Stacey Gabriel; David B Jaffe; Eric S Lander; Chad Nusbaum
Journal:  Nat Biotechnol       Date:  2009-02-01       Impact factor: 54.908

View more
  30 in total

Review 1.  Ontogeny, Genetics, Molecular Biology, and Classification of B- and T-Cell Non-Hodgkin Lymphoma.

Authors:  Russell James Hubbard Ryan; Ryan Alan Wilcox
Journal:  Hematol Oncol Clin North Am       Date:  2019-05-18       Impact factor: 3.722

Review 2.  Diagnosis and classification of lymphoma: Impact of technical advances.

Authors:  Elaine S Jaffe
Journal:  Semin Hematol       Date:  2018-05-29       Impact factor: 3.851

3.  A high definition picture of key genes and pathways mutated in pediatric follicular lymphoma.

Authors:  Federica Lovisa; Andrea Binatti; Alessandro Coppe; Simona Primerano; Elisa Carraro; Marta Pillon; Marco Pizzi; Vincenza Guzzardo; Salvatore Buffardi; Fulvio Porta; Piero Farruggia; Raffaela De Santis; Pietro Bulian; Giuseppe Basso; Elena Lazzari; Emanuele S G d'Amore; Stefania Bortoluzzi; Lara Mussolin
Journal:  Haematologica       Date:  2019-02-28       Impact factor: 9.941

Review 4.  Understanding the New WHO Classification of Lymphoid Malignancies: Why It's Important and How It Will Affect Practice.

Authors:  Elaine S Jaffe; Paul M Barr; Sonali M Smith
Journal:  Am Soc Clin Oncol Educ Book       Date:  2017

Review 5.  Clinical utility of recently identified diagnostic, prognostic, and predictive molecular biomarkers in mature B-cell neoplasms.

Authors:  Arantza Onaindia; L Jeffrey Medeiros; Keyur P Patel
Journal:  Mod Pathol       Date:  2017-06-30       Impact factor: 7.842

Review 6.  From genetics to the clinic: a translational perspective on follicular lymphoma.

Authors:  Sarah Huet; Pierre Sujobert; Gilles Salles
Journal:  Nat Rev Cancer       Date:  2018-02-09       Impact factor: 60.716

7.  Mutations of MAP2K1 are frequent in pediatric-type follicular lymphoma and result in ERK pathway activation.

Authors:  Janine Schmidt; Joan Enric Ramis-Zaldivar; Ferran Nadeu; Blanca Gonzalez-Farre; Alba Navarro; Caoimhe Egan; Ivonne Aidee Montes-Mojarro; Teresa Marafioti; Jose Cabeçadas; Jon van der Walt; Stefan Dojcinov; Andreas Rosenwald; German Ott; Irina Bonzheim; Falko Fend; Elias Campo; Elaine S Jaffe; Itziar Salaverria; Leticia Quintanilla-Martinez
Journal:  Blood       Date:  2017-05-22       Impact factor: 22.113

Review 8.  Follicular lymphoma, a B cell malignancy addicted to epigenetic mutations.

Authors:  Koorosh Korfi; Sara Ali; James A Heward; Jude Fitzgibbon
Journal:  Epigenetics       Date:  2017-01-20       Impact factor: 4.528

9.  Distinct molecular profile of IRF4-rearranged large B-cell lymphoma.

Authors:  Joan Enric Ramis-Zaldivar; Blanca Gonzalez-Farré; Olga Balagué; Verónica Celis; Ferran Nadeu; Julia Salmerón-Villalobos; Mara Andrés; Idoia Martin-Guerrero; Marta Garrido-Pontnou; Ayman Gaafar; Mariona Suñol; Carmen Bárcena; Federico Garcia-Bragado; Maitane Andión; Daniel Azorín; Itziar Astigarraga; Maria Sagaseta de Ilurdoz; Constantino Sábado; Soledad Gallego; Jaime Verdú-Amorós; Rafael Fernandez-Delgado; Vanesa Perez; Gustavo Tapia; Anna Mozos; Montserrat Torrent; Palma Solano-Páez; Alfredo Rivas-Delgado; Ivan Dlouhy; Guillem Clot; Anna Enjuanes; Armando López-Guillermo; Pallavi Galera; Matthew J Oberley; Alanna Maguire; Colleen Ramsower; Lisa M Rimsza; Leticia Quintanilla-Martinez; Elaine S Jaffe; Elías Campo; Itziar Salaverria
Journal:  Blood       Date:  2020-01-23       Impact factor: 22.113

10.  Follicular lymphoma t(14;18)-negative is genetically a heterogeneous disease.

Authors:  Dominik Nann; Joan Enric Ramis-Zaldivar; Inga Müller; Blanca Gonzalez-Farre; Janine Schmidt; Caoimhe Egan; Julia Salmeron-Villalobos; Guillem Clot; Sven Mattern; Franziska Otto; Barbara Mankel; Dolors Colomer; Olga Balagué; Vanessa Szablewski; Carmen Lome-Maldonado; Lorenzo Leoncini; Stefan Dojcinov; Andreas Chott; Christiane Copie-Bergman; Irina Bonzheim; Falko Fend; Elaine S Jaffe; Elias Campo; Itziar Salaverria; Leticia Quintanilla-Martinez
Journal:  Blood Adv       Date:  2020-11-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.